JP2004505640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004505640A5 JP2004505640A5 JP2002518278A JP2002518278A JP2004505640A5 JP 2004505640 A5 JP2004505640 A5 JP 2004505640A5 JP 2002518278 A JP2002518278 A JP 2002518278A JP 2002518278 A JP2002518278 A JP 2002518278A JP 2004505640 A5 JP2004505640 A5 JP 2004505640A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- human urocortin
- dna
- identification number
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 50
- 101000939391 Homo sapiens Urocortin Proteins 0.000 description 22
- 102000053170 human UCN Human genes 0.000 description 22
- 150000001413 amino acids Chemical group 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000004963 pathophysiological condition Effects 0.000 description 3
- 108091005470 CRHR2 Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 2
- 101710198652 Corticotropin-releasing factor receptor 1 Proteins 0.000 description 2
- 102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- 229930182845 D-isoleucine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- 229930182819 D-leucine Natural products 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- HPYDSVWYXXKHRD-VIFPVBQESA-N Tyr-Gly Chemical group [O-]C(=O)CNC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-VIFPVBQESA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22325500P | 2000-08-04 | 2000-08-04 | |
| US60/223,255 | 2000-08-04 | ||
| US27396901P | 2001-03-07 | 2001-03-07 | |
| US60/273,969 | 2001-03-07 | ||
| PCT/US2001/023976 WO2002012307A1 (en) | 2000-08-04 | 2001-07-31 | Urocortin proteins and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004505640A JP2004505640A (ja) | 2004-02-26 |
| JP2004505640A5 true JP2004505640A5 (enExample) | 2008-09-25 |
| JP4873825B2 JP4873825B2 (ja) | 2012-02-08 |
Family
ID=26917597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002518278A Expired - Fee Related JP4873825B2 (ja) | 2000-08-04 | 2001-07-31 | ウロコルチン蛋白質及びその利用 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US6838274B2 (enExample) |
| EP (1) | EP1305334B1 (enExample) |
| JP (1) | JP4873825B2 (enExample) |
| KR (1) | KR100879232B1 (enExample) |
| CN (1) | CN1484650B (enExample) |
| AT (1) | ATE408622T1 (enExample) |
| AU (2) | AU8468301A (enExample) |
| CA (1) | CA2418144C (enExample) |
| CY (1) | CY1110424T1 (enExample) |
| DE (1) | DE60135850D1 (enExample) |
| DK (1) | DK1305334T3 (enExample) |
| ES (1) | ES2313978T3 (enExample) |
| IL (2) | IL154102A0 (enExample) |
| PT (1) | PT1305334E (enExample) |
| RU (1) | RU2278871C2 (enExample) |
| WO (1) | WO2002012307A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2313978T3 (es) * | 2000-08-04 | 2009-03-16 | Research Development Foundation | Proteinas urocortina y sus usos. |
| US20020082409A1 (en) | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| AU2002306853B2 (en) | 2001-03-15 | 2006-07-06 | Research Development Foundation | Urocortin-III and uses thereof |
| US6936585B2 (en) | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| WO2008047241A2 (en) * | 2006-10-16 | 2008-04-24 | Conjuchem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
| CA2692039C (en) * | 2007-06-13 | 2019-07-02 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |
| US20100184680A1 (en) * | 2007-09-11 | 2010-07-22 | Dorian Bevec | Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| JP2010539058A (ja) * | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのｔｒａｐ−１４ |
| US20120238509A1 (en) * | 2009-08-28 | 2012-09-20 | Research Development Foundation | Urocortin 2 analogs and uses thereof |
| US9314506B2 (en) | 2011-10-24 | 2016-04-19 | Research Development Foundation | Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors |
| BR112014020127A2 (pt) * | 2012-02-14 | 2020-06-30 | The Regents Of The University Of Calefornia | métodos para tratamento, melhoramento ou proteção (prevenção) de um indivíduo ou um paciente, e de uma disfunção, uma doença, uma infecção ou uma condição, e, método para suprimir o ganho de peso, ou suprimir o apepite, ou estimular ou iniciar a perda de peso |
| JOP20170153A1 (ar) * | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| WO2020176807A1 (en) | 2019-02-27 | 2020-09-03 | Vanderbilt University | Methods of treating trigeminal nerve pain |
| CN110826145B (zh) * | 2019-09-09 | 2020-08-28 | 西安工业大学 | 基于超启发式马氏链进化的汽车多参数运行工况设计方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997000063A2 (en) | 1995-06-13 | 1997-01-03 | The Salk Institute For Biological Studies | Urocortin peptides |
| ES2313978T3 (es) | 2000-08-04 | 2009-03-16 | Research Development Foundation | Proteinas urocortina y sus usos. |
| US20020082409A1 (en) | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
-
2001
- 2001-07-31 ES ES01963759T patent/ES2313978T3/es not_active Expired - Lifetime
- 2001-07-31 DK DK01963759T patent/DK1305334T3/da active
- 2001-07-31 WO PCT/US2001/023976 patent/WO2002012307A1/en not_active Ceased
- 2001-07-31 JP JP2002518278A patent/JP4873825B2/ja not_active Expired - Fee Related
- 2001-07-31 CN CN018157831A patent/CN1484650B/zh not_active Expired - Fee Related
- 2001-07-31 DE DE60135850T patent/DE60135850D1/de not_active Expired - Lifetime
- 2001-07-31 PT PT01963759T patent/PT1305334E/pt unknown
- 2001-07-31 KR KR1020037001559A patent/KR100879232B1/ko not_active Expired - Fee Related
- 2001-07-31 RU RU2003105897/13A patent/RU2278871C2/ru not_active IP Right Cessation
- 2001-07-31 EP EP01963759A patent/EP1305334B1/en not_active Expired - Lifetime
- 2001-07-31 US US09/919,473 patent/US6838274B2/en not_active Expired - Lifetime
- 2001-07-31 AT AT01963759T patent/ATE408622T1/de active
- 2001-07-31 IL IL15410201A patent/IL154102A0/xx unknown
- 2001-07-31 CA CA2418144A patent/CA2418144C/en not_active Expired - Fee Related
- 2001-07-31 AU AU8468301A patent/AU8468301A/xx active Pending
- 2001-07-31 AU AU2001284683A patent/AU2001284683B2/en not_active Ceased
-
2003
- 2003-01-23 IL IL154102A patent/IL154102A/en not_active IP Right Cessation
-
2004
- 2004-10-25 US US10/973,092 patent/US7223846B2/en not_active Expired - Lifetime
-
2007
- 2007-04-05 US US11/784,317 patent/US7638607B2/en not_active Expired - Fee Related
-
2008
- 2008-12-17 CY CY20081101461T patent/CY1110424T1/el unknown
-
2009
- 2009-12-07 US US12/632,715 patent/US8044025B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Odell et al. | Antibacterial activity of peptides homologous to a loop region in human lactoferrin | |
| JP2004505640A5 (enExample) | ||
| JP2002500043A5 (enExample) | ||
| HUT70459A (en) | Analogs of pth | |
| NZ505880A (en) | IL-18 receptor polypeptides | |
| JP2004506432A5 (enExample) | ||
| HU202921B (en) | Process for producing coding dns for human tumor necrosis factor the corresponding polypeptide with utilizing them and pharmaceutical compositions containing this polypeptide as active component | |
| Callaway et al. | Modification of the C terminus of cecropin is essential for broad-spectrum antimicrobial activity | |
| JP2002514418A5 (enExample) | ||
| RU2003105897A (ru) | Белки урокортина и их применения | |
| CA2328140A1 (en) | Method of inhibiting osteoclast activity | |
| PT1931705E (pt) | Processo para a amidação de polipéptidos com aminoácidos básicos na extremidade c-terminal recorrendo a endoproteases específicas | |
| JP2003530124A5 (enExample) | ||
| CA2461443A1 (en) | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use | |
| JP2002517193A5 (enExample) | ||
| WO1994010199A1 (en) | Expression and purification of cloned human alpha-fetoprotein | |
| US5824788A (en) | Cloning of gene encoding the GP28.5 protein of toxoplasma gondii; peptide fragments of said protein and their applications | |
| DE69935599D1 (de) | Modifizierte hcv peptid-impfstoffe | |
| DE60336353D1 (de) | Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung | |
| JP2003334088A5 (enExample) | ||
| US6255067B1 (en) | cDNA encoding peptidyl-glycine alpha-amidating monooxygenase (PAM) | |
| AU9391598A (en) | Beta-defensins | |
| WO1992014834A1 (en) | Insulin-like growth factor binding protein | |
| CA2301902A1 (en) | Novel extracellular serine protease | |
| WO1997016550A1 (en) | Polypeptide fragments derived from the obese gene product |